Case Report: Botulinum Toxin-A for Complication of Exposure Keratopathy Following Frontalis-Orbicularis Oculi Muscle Flap Shortening

Chun-Chieh Lai¹,² and Chia-Chen Lin²*

¹ Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ² Department of Ophthalmology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Background: Lagophthalmos with exposure keratopathy is a potential vision-threatening complication following surgery for blepharoptosis. We report three cases successfully treated with botulinum toxin-A (Botox®, Allergan, Irvine, USA) for this complication.

Cases: Three patients presented with severe blepharoptosis after surgery for orbital and frontal base tumors. They obtained good appearances after frontalis-orbicularis oculi muscle (FOOM) flap shortening. However, exposure keratopathy developed after the surgery despite frequent use of topical lubricants and autologous serum eye drops. We injected 5-10 units of botulinum toxin-A around the central supra-brow area, which was near the origin of the FOOM flap. One week later, they developed ptosis and could close the eye completely. The corneal defect gradually resolved. They recovered from ptosis 3 months later and never required a second injection.

Observations: Lagophthalmos with exposure keratopathy is a potential vision-threatening complication following surgery for blepharoptosis. In severe cases, surgical revision should be considered to partially or totally release the FOOM flap attachment, which also decreases its function permanently. In this case series, we demonstrated that injecting botulinum toxin-A may be a promising method to manage this complication without permanently affecting the function of the FOOM flap.

Conclusions: A botulinum toxin-A injection may be an effective treatment for patients developing exposure keratopathy after FOOM flap surgery.

Keywords: blepharoptosis, botulinum toxin-A, exposure keratopathy, frontalis-orbicularis oculi muscle flap, lagophthalmos

INTRODUCTION

Blepharoptosis is a complex disease with multiple etiologies, including previous orbital surgery and trauma, which are especially difficult to manage (1, 2). The choice of surgical technique depends largely on the levator muscle function (LMF) (3, 4). For fair to good LMF, the Müller's muscle-conjunctival resection, levator muscle advancement or resection may be adequate (5).
A modification of the Putterman technique, the elevator muscle anterior resection, provides even better accuracy and reliability for ptosis correction (6). However, for patients with poor LMF, typically \( \leq 4 \text{mm} \), supramaximal levator resection beyond Whitnall ligament has to be done. The technique is currently less performed for previous studies have shown that the upper lids became less elastic after large portions of thelevator muscle were severed. Restrictions of downward saccadic movements, reduced blinking, and abnormal lid contour were reported postoperatively (7). The frontalis sling operation, a more popular and reliable surgical technique, relies on the recruitment of the ipsilateral frontalis muscle to lift the eyelid (8). Postoperative lagophthalmos, however, is a common complication. This technique is also complicated by the risks of infection and granuloma formation associated with the synthetic materials used for suspension, or the need of a second donor site if autologous materials are used (9).

In the 2000s, Lai et al. introduced the frontalis-orbicularis oculi muscle (FOOM) flap shortening technique to correct blepharoptosis with poor LMF (10). The technique is based on finding that the vertically oriented frontalis muscle is continuous with the horizontally oriented orbicularis oculi muscle (11). The FOOM flap is harvested through dissection beneath the orbicular oculi muscle beyond the supraorbital rim (Figure 1A). After the desired position of the upper lid margin is decided, the local flap is anchored to the upper tarsus. The FOOM flap has demonstrated both contractility and elasticity, properties not possessed by a frontalis sling. This operation also spares the need of a second surgical site (12).

In this article, we present three cases who underwent FOOM flap shortening technique for blepharoptosis with poor LMF due to previous orbital surgeries. However, they developed lagophthalmos with exposure keratopathy, a possible vision-threatening complication following this surgery. The suspension power of FOOM flap is generated mainly from the frontalis muscle, and the orbicularis oculi muscle serves as a connector to elevate the ptotic eyelid. Therefore, if the power of frontalis muscle could be reduced, such as by injections of neurotoxic drug at the supra-brow area, the origin of the FOOM flap, lagophthalmos may be resolved (Figure 1B). Here, we report the effect of botulinum toxin-A (Botox\textsuperscript{®}, Allergan, Irvine, U.S.A.) as a treatment for exposure keratopathy, a complication of FOOM flap surgery.

**CASE REPORTS**

**Case 1**

A 63-year-old gentleman developed complete blepharoptosis for 6 months after surgery for an orbital lymphoma in the right eye (Figure 2A). We performed FOOM flap shortening, after which he obtained a symmetric appearance (Figure 2B). The margin reflex distance 1 (MRD1) was 2.5 mm, and the function of FOOM flap (upper eyelid excursion) was 4 mm postoperatively (Figures 2C,D). However, he developed lagophthalmos with exposure keratopathy following cataract surgery on the right eye, which was performed 1 year after. Due to the fact that there was a persistent corneal defect in spite of our best efforts with conservative treatments such as topical lubricants and autologous serum eye drops, we injected 5 units of botulinum toxin-A at the central supra-brow area. One week later, he developed blepharoptosis with MRD1 of 1 mm and the function of FOOM flap was reduced from 4 mm to nearly 0 (Figures 2E-H). He could close his right eye completely and experienced an improvement in his ocular surface. The corneal epithelial defect healed gradually. He recovered from the ptosis with MRD1 of 2.5 mm 3 months after the injection (Figure 3) and did not require a second injection even after 1 year.

**Case 2**

A 58-year-old gentleman developed blepharoptosis with MRD1 of 0 mm and LMF of 4 mm for 7 months after surgery for a lacrimal gland tumor in the left eye. The blepharoptosis dramatically improved with MRD1 measured 4 mm immediately after FOOM flap shortening. Unfortunately, exposure keratopathy developed soon. Due to the progressive condition with a persistent corneal defect in spite of the frequent use of topical lubricants and autologous serum eye drops, medial and lateral tarsorrhaphy were performed. However, the sutures for tarsorrhaphy disrupted in 5 days due to the very powerful FOOM flap. Thus, we injected 10 units of botulinum toxin-A at the central supra-brow area in order to diminish its power. Four days thereafter, the upper eyelid excursion was reduced from 12 to 4 mm. He developed blepharoptosis and could close his left eye more completely. After that, the corneal defect gradually resolved. He also recovered from blepharoptosis with MRD1 of 3 mm after 3 months.
Case 3
A 66-year-old gentleman presented with complete ptosis of the left eye after an operation for left frontal base meningioma 1 year ago. The MRD1 was −4 mm and LMF was 0 mm. The patient received FOOM flap shortening. Resolution of ptosis with MRD1 of 2 mm and upper eyelid excursion of 4 mm were achieved. However, after 1 month, exposure keratopathy developed despite the use of topical lubricants. We injected 10 units of botulinum toxin-A at the central supra-brow area. A week later, the MRD1 reduced to −1 mm with nearly no FOOM flap function. The exposure keratopathy gradually resolved. Four months after the injection, the MRD1 restored to 2 mm and stabilized. No second injection of botulinum toxin-A was needed.

DISCUSSION
There have been several reports regarding the utilization of either the advanced frontalis or orbicularis oculi muscle flap to lift the ptotic eyelid (13). Lai et al. first reported the FOOM flap shortening technique for blepharoptosis caused by various etiologies (10, 14). This technique provides several advantages, including a good operative field with no risk of intra-orbital neurovascular injury because the orbital septum is not opened (15, 16), which is an intraoperative challenge frequently encountered in secondary levator muscle repair. The situation may be even more complicated especially following an extensive orbital injury, including surgical trauma, which results in distorted orbital structure and severe cicatrization. In addition, the FOOM flap not only elevates the upper eyelid but also increases its excursion, which is hard to achieve with supramaximal levator resection or the frontalis sling operation.

Despite its many advantages, lagophthalmos with exposure keratopathy is a possible vision-threatening complication associated with this surgery. In most cases, surgeons may prescribe lubricants and normal eyelid closure may resume in 3-6 months; however, some patients develop irreversible
is to decrease the power of the frontalis muscle. In our cases, we injected botulinum toxin-A at central supra-brow area around the origin of FOOM flap. Indeed, their FOOM flap functions were reduced after 4-7 days and recovered 3 months thereafter. Even though they developed blepharoptosis again after this procedure, the appearances were relatively acceptable when compared to those with tarsorrhaphy. Most importantly, the effect of botulinum toxin-A, in contrast to the surgical revision, was temporary and the FOOM flap would recover its elevation power with resolution of blepharoptosis. Therefore, we suggest that injections of botulinum toxin-A may be a promising method to treat exposure keratopathy following FOOM flap shortening without permanent effects on the function of the FOOM flap (Table 1).

**CONCLUSIONS**

In blepharoptosis with poor LMF related to orbital trauma including surgery, FOOM flap shortening is an alternative technique to achieve not only a satisfactory appearance but also good function of the upper eyelid, as in the three cases reported herein. Still, lagophthalmos with exposure keratopathy is a potential complication. Botulinum toxin-A injection might be a very effective treatment for patients developing this complication after FOOM flap surgery.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

C-CLai collected the clinical data and prepared the manuscript. Both authors reviewed and revised the manuscript.

**FUNDING**

The publication fees are funded by the Department of Ophthalmology, National Cheng Kung University Hospital.

**REFERENCES**

1. Frueh BR. The mechanistic classification of ptosis. *Ophthalmology*. (1980) 87:1019-21. doi: 10.1016/S0161-6420(80)35135-X
2. Krohel GB. Blepharoptosis after traumatic third-nerve palsies. *Am J Ophthalmol.* (1979) 88:598-601. doi: 10.1016/0002-9394(79)90521-X
3. Deemstra W, Melis P, Kon M, Werker P. Correction of severe blepharoptosis. *Ann Plast Surg.* (1996) 36:348-53. doi: 10.1097/00000637-199604000-00004
Lai and Lin

Botulinum Toxin-A for Exposure Keratopathy

4. Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. *Ophthalmology*. (1996) 103:623-30. doi: 10.1016/S0161-6420(96)30643-X

5. Díaz-Manera J, Luna S, Roig C. Ocular ptosis: differential diagnosis and treatment. *Curr Opin Neurol*. (2018) 31:618-27. doi: 10.1097/WCO.0000000000000600

6. Zigiotti GL, Delia G, Genga P, Pichi F, Rechichi M, Jaroudi MO, et al. Elevator muscle anterior resection: a new technique for blepharoptosis. *J Craniofac Surg*. (2016) 27:201-3. doi: 10.1097/SCS.0000000000002290

7. Cruz AA, Akaishi PM, Mendonca AK, Bernardini F, Devoto M, Garcia DM. Supramaximal levator resection for unilateral congenital ptosis: cosmetic and functional results. *Ophthalmic Plast Reconstr Surg*. (2014) 30:366-71. doi: 10.1097/IOP.0000000000000105

8. Kersten RC, Bernardini FP, Khouri L, Moin M, Roumeliotis AA, Kulwin DR. Unilateral frontalis sling for the surgical correction of unilateral poor-function ptosis. *Ophthalmic Plast Reconstr Surg*. (2005) 21:412-6; discussion 6-7. doi: 10.1097/01.iop.0000180068.1744.80

9. Takahashi Y, Leibovitch I, Kakizaki H. Frontalis suspension surgery in upper eyelid blepharoptosis. *Open Ophthalmol J*. (2010) 4:91-7. doi: 10.2174/1874364101004010091

10. Lai CS, Chang KP, Lai CH, Huang SH, Tsai CC, Lin SD. A dynamic technique for the treatment of severe or recurrent blepharoptosis: frontalis-ocular muscle flap shortening. *Ophthalmologica*. (2009) 223:376-82. doi: 10.1159/000228589

11. Knize DM. An anatomically based study of the mechanism of eyebrow ptosis. *Plast Reconstr Surg*. (1996) 97:1321-33. doi: 10.1097/00006534-199606000-00001

12. Huang SH, Lee CC, Lai HT, Takahashi H, Wang YC, Lai CS. The function-preserving frontalis orbicularis oculi muscle flap for the correction of severe blepharoptosis with poor levator function. *Aesthet Surg J*. (2021). 41:NP280-6. doi: 10.1093/aaj/sjaaz429

13. Ramirez OM, Pena G. Frontalis muscle advancement: a dynamic structure for the treatment of severe congenital eyelid ptosis. *Plast Reconstr Surg*. (2004) 113:1841-9; discussion 30-1. doi: 10.1097/01.PRS.0000117664.07831.48

14. Lai CS, Lai CH, Huang SH, Sun IF, Chang KP, Lee SS, et al. A new trend for the treatment of blepharoptosis: frontalis-ocular muscle flap shortening technique. *J Plast Reconstr Aesthet Surg*. (2010) 63:233-9. doi: 10.1016/j.bjps.2008.11.018

15. Lai CS, Chang KP, Lee SS, Hsieh TY, Lai HT, Huang YH, et al. The role of frontalis orbicularis oculi muscle flap for correction of blepharoptosis with poor levator function. *Ann Plast Surg*. (2013) 71(Suppl 1):S29-36. doi: 10.1097/SAP.000000000000043

16. Lai CS, Lai YW, Huang SH, Lee SS, Chang KP, Chen AD. Surgical correction of the intractable blepharoptosis in patients with ocular myasthenia gravis. *Ann Plast Surg*. (2016) 76(Suppl 1):S55-9. doi: 10.1097/SAP.0000000000000695

17. Shih MJ, Liao SL, Lu HY. A single transcutaneous injection with Botox for dysthyroid lid retraction. *Eye*. (2004) 18:466-9. doi: 10.1038/sj.eye.6700690

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Lai and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.